Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Ndounga Diakou, Lee Aymar ^a   Trinquart, Ludovic ^b   Hróbjartsson, Asbjørn ^c   Barnes, Caroline ^a   Yavchitz, Amelie ^a   Ravaud, Philippe ^a   Boutron, Isabelle ^a  

^a PARIS DESCARTES UNIVERSITY   (France)

^b HÔTEL DIEU   (France)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUDICATION COMMITTEE; ADVISORY COMMITTEE; ARTICLE; CENTRAL ADJUDICATION OUTCOME ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; COMPARATIVE STUDY; HUMAN; ONSITE OUTCOME ASSESSMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 85041800050     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.MR000043     Document Type: Article

References (27)

1. Bagos PG. On the covariance of two correlated log-odds ratios. Statistics in Medicine 2012;31(14):1418-31. [PUBMED: 22302419]
2. Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Journal of Rheumatology 1997;24(4):799-802. [PUBMED: 9101522]
3. Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A, Ravaud P. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Medicine 2006;3(10):e425.
4. Boutron I, Guittet L, Estellat C, Moher D, Hrobjartsson A, Ravaud P. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Medicine 2007;4(2):e61. [PUBMED: 17311468]
5. Dechartres A, Boutron I, Roy C, Ravaud P. Inadequate planning and reporting of adjudication committees in clinical trials: recommendation proposal. Journal of Clinical Epidemiology 2009;62(7):695-702.
6. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [PUBMED: 3802833]
7. Eriksson BI, Smith JJ, Caprini J, Hantel S, Clemens A, Feuring M, et al. Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials. Thrombosis Research 2012;130(3):396-402.
8. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, et al. Do we need to adjudicate major clinical events?. Clinical Trials 2008;5(1):56-60. [PUBMED: 18283081]
9. Hata J, Arima H, Zoungas S, Fulcher G, Pollock C, Adams M, et al. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial. PloS One 2013;8(2):e55807. [PUBMED: 23390553]
10. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. [PUBMED: 22008217]
11. Horsley T, Dingwall O, Sampson M. Checking reference lists to find additional studies for systematic reviews. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.MR000026.pub2]
12. Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 2012;344:e1119.
13. Kirwan BA, Lubsen J, de Brouwer S, Danchin N, Battler A, Bayes de Luna A, et al. Diagnostic criteria and adjudication process both determine published event-rates: the ACTION trial experience. Contemporary Clinical Trials 2007;28(6):720-9.
14. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):180-6.
15. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Current Controlled Trials in Cardiovascular Medicine 2001;2(4):187-94.
16. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. American Heart Journal 2002;143(2):242-8.
17. Mahaffey KW, Wampole JL, Stebbins A, Berdan LG, McAfee D, Rorick TL, et al. Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Contemporary Clinical Trials 2011;32(2):178-87.
18. Moustgaard H, Bello S, Miller FG, Hróbjartsson A. Subjective and objective outcomes in randomized clinical trials: definitions differed in methods publications and were often absent from trial reports. Journal of Clinical Epidemiology 2014;67(12):1327-34.
19. Naslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. European Heart Journal 1999;20(10):771-7. [PUBMED: 10329069]
20. O'Connor CM, Gottlieb S, Bourque JM, Krause-Steinrauf H, Anand I, Anderson JL, et al. Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. American Journal of Cardiology 2005;95(5):558-64.
21. Pogue J, Walter SD, Yusuf S. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clinical Trials 2009;6(3):239-51. [PUBMED: 19528133]
22. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
23. Stuck AK, Fuhrer E, Limacher A, Mean M, Aujesky D. Adjudication-related processes are underreported and lack standardization in clinical trials of venous thromboembolism: a systematic review. Journal of Clinical Epidemiology 2014;67(3):278-84. [PUBMED: 24290147]
24. Vannabouathong C, Sprague S, Bhandari M. Guidelines for fracture healing assessments in clinical trials. Part I: definitions and endpoint committees. Injury 2011;42(3):314-6.
25. Vannabouathong C, Saccone M, Sprague S, Schemitsch EH, Bhandari M. Adjudicating outcomes: fundamentals. Journal of Bone and Joint Surgery. American Volume 2012;94(Suppl 1):70-4. [PUBMED: 22810452]
26. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, et al. Efficacy and safety of maribavir dosed at 100 μg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. American Journal of Transplantation 2012;12(11):3021-30.
27. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336(7644):601-5.